Availability of internationally controlled pharmaceutical opioids for medical use has stabilized in recent years.Availability of pharmaceutical opioids for medical use more than doubled between 1998 and 2024 – driven by a strong increase until 2013, followed by a decline and partial recovery in…
There remains a large discrepancy between the Global North and the Global South in the availability of internationally controlled pharmaceutical opioids for medical use - even though the gap is declining.Between 2015 and 2024, the per capita availability of pharmaceutical opioids for medical use in…
The legalization of cannabis for non-medical use has followed a continuum driven by the progressive normalization of its use – a process that has also influenced developments elsewhereAs of December 2025, Canada, Uruguay and 28 jurisdictions in the United States had enacted legal provisions, either…
Seven substances dominate the global availability of opioids under international control for medical consumption.Expressed in S-DDDs (defined daily doses for statistical purposes), methadone, followed by hydrocodone, fentanyl, buprenorphine, oxycodone, codeine (including preparations) and morphine…
The use of buprenorphine and methadone for medical purposes continues to expandMethadone and buprenorphine are the main substances used in substitution treatment for opioid dependent persons worldwide. Availability of both substances for medical use rose 10-fold over the last two decades and…
